| The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases D Soler, T Chapman, LL Yang, T Wyant, R Egan, ER Fedyk Journal of Pharmacology and Experimental Therapeutics 330 (3), 864-875, 2009 | 542 | 2009 |
| IL-8 production in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by … RS Smith, ER Fedyk, TA Springer, N Mukaida, BH Iglewski, RP Phipps The Journal of Immunology 167 (1), 366-374, 2001 | 354 | 2001 |
| An overview of the mechanism of action of the monoclonal antibody vedolizumab T Wyant, E Fedyk, B Abhyankar Journal of Crohn's and Colitis 10 (12), 1437-1444, 2016 | 291 | 2016 |
| Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing ER Fedyk, D Jones, HOD Critchley, RP Phipps, TM Blieden, TA Springer The Journal of Immunology 166 (9), 5749-5754, 2001 | 194 | 2001 |
| Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. ER Fedyk, RP Phipps Proceedings of the National Academy of Sciences 93 (20), 10978-10983, 1996 | 194 | 1996 |
| CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes D Soler, TR Chapman, LR Poisson, L Wang, J Cote-Sierra, M Ryan, ... The Journal of Immunology 177 (10), 6940-6951, 2006 | 166 | 2006 |
| A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab M Rosario, NL Dirks, C Milch, A Parikh, M Bargfrede, T Wyant, E Fedyk, ... Clinical pharmacokinetics 56, 1287-1301, 2017 | 164 | 2017 |
| Exclusive Antagonism of the α4β7 Integrin by Vedolizumab Confirms the Gut-selectivity of This Pathway in Primates ER Fedyk, T Wyant, LL Yang, V Csizmadia, K Burke, H Yang, VJ Kadambi Inflammatory bowel diseases 18 (11), 2107-2119, 2012 | 150 | 2012 |
| Role of regulator of G protein signaling 16 in inflammation-induced T lymphocyte migration and activation E Lippert, DL Yowe, JA Gonzalo, JP Justice, JM Webster, ER Fedyk, ... The Journal of Immunology 171 (3), 1542-1555, 2003 | 100 | 2003 |
| Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis KG Haanstra, SO Hofman, DM Lopes Estêvão, ELA Blezer, J Bauer, ... The Journal of Immunology 190 (5), 1961-1973, 2013 | 91 | 2013 |
| Maturation decreases responsiveness of human bone marrow B lineage cells to stromal-derived factor 1 (SDF-1) ER Fedyk, DH Ryan, I Ritterman, TA Springer Journal of leukocyte biology 66 (4), 667-673, 1999 | 80 | 1999 |
| A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: coexpression of EP1, EP2, EP3β and EP4 ER Fedyk, JM Ripper, DM Brown, RP Phipps Molecular immunology 33 (1), 33-45, 1996 | 75 | 1996 |
| In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes T Wyant, L Yang, E Fedyk MAbs 5 (6), 842-850, 2013 | 61 | 2013 |
| Regulation of IgE and cytokine production by cAMP: implications for extrinsic asthma ER Fedyk, A Adawi, RJ Looney, RP Phipps Clinical immunology and immunopathology 81 (2), 101-113, 1996 | 59 | 1996 |
| Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro V Csizmadia, A Raczynski, E Csizmadia, ER Fedyk, J Rottman, CL Alden Neurotoxicology 29 (2), 232-243, 2008 | 41 | 2008 |
| Preliminary results from a phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM) AY Krishnan, KK Patel, P Hari, S Jagannath, R Niesvizky, RW Silbermann, ... Blood 134, 140, 2019 | 29 | 2019 |
| Reactive oxygen species and not lipoxygenase products are required for mouse B-lymphocyte activation and differentiation ER Fedyk, RP Phipps International journal of immunopharmacology 16 (7), 533-546, 1994 | 29 | 1994 |
| Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects ER Fedyk, L Zhao, A Koch, G Smithson, J Estevam, G Chen, G Lahu, ... British Journal of Clinical Pharmacology 86 (7), 1314-1325, 2020 | 28 | 2020 |
| PGE2 Regulation of B Lymphocytes and T Helper 1 and T Helper 2 Cells: Induction of Inflammatory versus Allergic Responses ER Fedyk, DM Brown, RP Phipps Eicosanoids and other Bioactive Lipids in Cancer, Inflammation, and …, 1997 | 27 | 1997 |
| A reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys W Korver, M Carsillo, J Yuan, N Idamakanti, M Wagoner, P Shi, CQ Xia, ... Journal of Pharmacology and Experimental Therapeutics 370 (2), 182-196, 2019 | 26 | 2019 |
